uniQure N.V. (QURE)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch QURE
See up to 3 months of QURE. The 7-day demo opens the 1M and 3M ranges and puts QURE on your watchlist.
Start 7-day demoLatest QURE insider trades
About uniQure N.V. (QURE)
The SEC lists uniQure N.V. under CIK 0001590560, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
QURE Form 4 activity by transaction type, last 90 days
No Form 4 activity for QURE in the last 90 days.
QURE insider transactions (Form 4)
4041 Form 4 filings on record, the earliest from Dec 10, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christian Klemt - Officer | Open-market sale | Ordinary Shares | 6,217 footnote F1 | $23.86 footnote F2 | $148K | |
| ||||||
| Robert Gut - Director | Open-market sale | Ordinary Shares | 15,840 | $27.22 footnote F3 | $431K | |
| Robert Gut - Director | Open-market sale | Ordinary Shares | 15,594 | $27.30 | $426K | |
| Robert Gut - Director | Option exercise | Stock Option (Right to Buy) | 15,840 | $0.00 | - | |
| Robert Gut - Director | Option exercise | Ordinary Shares | 15,840 | $4.57 | $72K | |
| ||||||
| Jack Kaye - Director | Open-market sale | Ordinary Shares | 11,000 | $30.34 footnote F3 | $334K | |
| Jack Kaye - Director | Option exercise | Ordinary Shares | 17,810 | $14.08 | $251K | |
| Jack Kaye - Director | Open-market sale | Ordinary Shares | 17,810 | $30.33 footnote F4 | $540K | |
| Jack Kaye - Director | Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Jack Kaye - Director | Option exercise | Stock Option (Right to Buy) | 11,000 | $0.00 | - | |
| Jack Kaye - Director | Option exercise | Stock Option (Right to Buy) | 17,810 | $0.00 | - | |
| Jack Kaye - Director | Option exercise | Ordinary Shares | 10,000 | $7.37 | $74K | |
| Jack Kaye - Director | Open-market sale | Ordinary Shares | 10,000 | $30.36 footnote F2 | $304K | |
| Jack Kaye - Director | Option exercise | Ordinary Shares | 11,000 | $5.37 | $59K | |
| ||||||
| Christian Klemt - Officer | Option exercise | Ordinary Shares | 3,000 | $13.03 | $39K | |
| Christian Klemt - Officer | Open-market sale | Ordinary Shares | 3,000 | $40.04 | $120K | |
| Christian Klemt - Officer | Option exercise | Ordinary Shares | 15,000 | $5.37 | $81K | |
| Christian Klemt - Officer | Open-market sale | Ordinary Shares | 15,000 | $55.00 | $825K | |
| Christian Klemt - Officer | Option exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | - | |
| Christian Klemt - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Matthew C. Kapusta - Officer | Option exercise | Ordinary Shares | 51,316 | $7.53 | $386K | |
| Matthew C. Kapusta - Officer | Option exercise | Ordinary Shares | 175,000 | $6.22 | $1.09M | |
| Matthew C. Kapusta - Officer | Open-market sale | Ordinary Shares | 51,316 | $39.59 | $2.03M | |
| Matthew C. Kapusta - Officer | Open-market sale | Ordinary Shares | 60,000 | $40.04 | $2.40M | |
| Matthew C. Kapusta - Officer | Open-market sale | Ordinary Shares | 49,978 | $40.68 | $2.03M | |
| Matthew C. Kapusta - Officer | Open-market sale | Ordinary Shares | 5,022 | $41.69 | $209K | |
| Matthew C. Kapusta - Officer | Open-market sale | Ordinary Shares | 60,000 | $45.10 | $2.71M | |
| Matthew C. Kapusta - Officer | Option exercise | Stock Option (Right to Buy) | 51,316 | $0.00 | - | |
| Matthew C. Kapusta - Officer | Option exercise | Stock Option (Right to Buy) | 175,000 | $0.00 | - | |
| Walid Abi-Saab - Officer | Open-market sale | Ordinary Shares | 1,466 | $13.92 | $20K | |
| Leonard E. Post - Director | Open-market sale | Ordinary Shares | 2,112 | $14.45 | $31K | |
| Leonard E. Post - Director | Grant or award | Ordinary Shares | 7,970 | $0.00 | - | |
| Leonard E. Post - Director | Grant or award | Stock Option (Right to Buy) | 15,630 | $0.00 | - | |
| Matthew C. Kapusta - Officer | Option exercise | Ordinary Shares | 100,000 | $14.71 | $1.47M | |
| Matthew C. Kapusta - Officer | Open-market sale | Ordinary Shares | 100,000 | $15.03 | $1.50M | |
| Matthew C. Kapusta - Officer | Option exercise | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Christian Klemt - Officer | Grant or award | Ordinary Shares | 3,672 | $0.00 | - | |
| Christian Klemt - Officer | Open-market sale | Ordinary Shares | 1,796 | $7.55 | $14K | |
| Matthew C. Kapusta - Officer | Grant or award | Ordinary Shares | 10,494 | $0.00 | - | |
| Matthew C. Kapusta - Officer | Open-market sale | Ordinary Shares | 3,418 | $7.63 | $26K | |
Item 7.01, 9.01
Item 7.01, 9.01
Item 2.02, 9.01
Item 1.01, 8.01, 9.01
Recent QURE Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
QURE insider trading FAQ
What is the latest insider trade for QURE?
uniQure N.V. (QURE) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-07. The full record for QURE runs to 41 Form 4 filings, the earliest from 2024-12-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying QURE stock?
No insider purchases of QURE were filed in the last 90 days.
How many insiders are selling QURE stock?
No insider sales of QURE were filed in the last 90 days. 65 sales are on record for this company.
Where can I see QURE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects QURE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Matthew C. Kapusta view on EDGAR
- - Walid Abi-Saab view on EDGAR
- - Jack Kaye view on EDGAR
- - Walid Abi-Saab view on EDGAR
- - Matthew C. Kapusta view on EDGAR
- - Matthew C. Kapusta view on EDGAR
- - Madhavan Balachandran view on EDGAR
- - Jack Kaye view on EDGAR
- - Madhavan Balachandran view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where QURE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow QURE with a 7-day demo
- QURE on your watchlist
- Every QURE Form 4 filing on record
- Up to 3 months of QURE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
